Clinical Trial Update: AMX0035 and Progressive Supranuclear Palsy [Phase 2, Phase 3]

View source ↗

Summary

AMX0035 is being tested in Phase 2 and Phase 3 trials for progressive supranuclear palsy, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: Progressive Supranuclear Palsy, PSP | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING